Rafi Mohammad is a seasoned pharmaceutical development professional currently serving as the Director at Bayer, where he spearheads innovative projects in the realm of cell and gene therapy formulation and drug product development. With over a decade of experience, Rafi has cultivated a robust expertise...
Rafi Mohammad is a seasoned pharmaceutical development professional currently serving as the Director at Bayer, where he spearheads innovative projects in the realm of cell and gene therapy formulation and drug product development. With over a decade of experience, Rafi has cultivated a robust expertise in the formulation and delivery of complex therapeutics, including siRNA, antibodies, and protein therapeutics. His role encompasses not only the strategic oversight of CMC (Chemistry, Manufacturing, and Controls) but also the hands-on leadership of a talented team of scientists dedicated to advancing cutting-edge biologics.
Under Rafi's guidance, Bayer has made significant strides in the formulation and process development of biologics, ensuring drug product device compatibility that meets the highest industry standards. His deep knowledge in pharmacology and molecular biology, combined with a strong foundation in protein chemistry, allows him to navigate the complexities of preclinical research, particularly in oncology and infectious diseases. Rafi's innovative approach leverages advanced techniques such as gold-bacteriophage nanotechnology, positioning Bayer at the forefront of therapeutic development.
Rafi is passionate about fostering a collaborative environment that encourages scientific exploration and creativity. His commitment to excellence in research and development (R&D) drives his team to push the boundaries of what's possible in therapeutic delivery systems. As he continues to lead impactful projects, Rafi remains dedicated to transforming the landscape of pharmaceutical development, ultimately improving patient outcomes through groundbreaking therapies.
